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This study is planned to evaluate the safety of glibenclamide 
(an anti-diabetic drug) therapy in the presence of 
carbamazepine (a prototype drug used to treat painful 
diabetic neuropathy) in healthy rats. The interaction 
mechanisms in preclinical studies help to avoid adverse 
effects when this particular combination was administered 
to patients suffering with painful diabetic neuropathy.
MATERIALS AND METHODS
Drugs and chemicals
Glibenclamide and carbamazepine are the gift samples 
from Alka Pharmaceuticals (Hyderabad, India). D-PBS 
INTRODUCTION
P-glycoprotein (P-gp) is a transmembrane protein, associated 
with a phenotype of multidrug resistance to certain anticancer 
drugs in mammalian cancer cells, that is able to pump a broad 
range of structurally and functionally unrelated compounds 
out of the cell by an ATP-dependent process. New in vitro 
models have been developed to predict in vivo P-gp activity, 
in which Caco-2 cell monolayers are widely used to estimate 
transepithelial passage of different P-gp substrates.[1,2] 
However, the correlation between this in vitro model and in 
vivo studies is rather poor. The use of everted gut sacs has 
been proposed as a new in vitro model for quantification of 
P-gp-mediated intestinal efflux for various drugs.
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ABSTRACT
The everted gut sac method was used to assess the role of the P-glycoprotein (P-gp) on the intestinal secretion 
of glibenclamide, a prototype of drug used to treat diabetic mellitus. The study included the evaluation of a P-gp 
modulator carbamazepine used at equimolar doses in the rat. Furthermore, the influence of carbamazepine on 
the disposition kinetics of glibenclamide in plasma was characterized. For the in vitro experiments, ileal sacs 
were incubated with glibenclamide in the presence or absence of carbamazepine. In the in vivo experiments, 
albino rats of either sex were randomly allocated to two groups (n = 6) and oral treatment with glibenclamide 
(3.6 mg/kg), alone and coadministration with carbamazepine (90 mg/kg). Blood samples were collected at an 
interval of 1, 2, 4, 6, and 8 h, respectively. Glibenclamide concentrations in both in vitro and in vivo samples 
were estimated by a sensitive RP-HPLC method. The rate of glibenclamide accumulation in the intestine wall of 
everted sacs was significantly lower after its incubation with carbamazepine when compared to glibenclamide 
alone treated. In the agreement with the in vivo and in vitro experiments, the presence of carbamazepine induced 
an enhancement in the concentrations of glibenclamide in plasma and gastrointestinal tract. The results obtained 
in this study, both under in vivo and in vitro conditions confirm the relevance of P-gp-mediated transport to the 
intestinal secretion of glibenclamide.
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(Sigma-Aldrich, USA), the HPLC grade methanol and 
acetonitrile of Qualigens Fine Chemicals, Mumbai were 
procured from local chemical suppliers. All other chemicals 
used were of analytical grade.
Animals 
Experiments were performed with albino rats procured 
from Mahaveera Enterprises (Hyderabad, AP, India), 
weighing between 180 and 210 g. The animals were 
housed in colony cages (four per cage) under conditions 
of standard lighting, temperature (22 ± 1°c) and humidity 
for at least 1 week before the beginning of experiment, 
to adjust to the new environment and to overcome stress 
possibly incurred during transit. During this period, they 
had free access to food and water. The experiments were 
planned after the approval of Institutional Animal Ethical 
Committee (IEAC), Vaagdevi College of Pharmacy, 
Warangal, AP, India.
METHODS
In vitro experiment
The experimental procedure was performed by modified 
method of Yumoto et al.[3] The whole small intestine was 
isolated and flushed with 50 mL of ice-cold saline after 
killing the animal by overdose of pentobarbital. The small 
intestine was divided into duodenum, jejunum, and ileum. 
Ileul segment was everted, and a 10-cm long sac was 
prepared (i.e., P-gp is more expressive in ileum). About 1 
mL of glibenclamide solution (1 mg/mL) was introduced 
into the everted sac (serosal side) and both ends of the 
sac were ligated tightly. The sac-containing glibenclamide 
solution was immersed into 30 mL of Dulbecco’s 
phosphate buffer solution (D-PBS) containing 25 mM of 
glucose, and the same concentration of carbamazepine 
in DMSO was introduced into the mucosal side and the 
solution was prewarmed and oxygenated throughout the 
experiment. The transport of glibenclamide from serosal 
to mucosal surface across the intestine was measured by 
collecting samples from the mucosal medium periodically 
at different intervals 0, 10, 20, 30, 60, 90, and 120 min and 
all samples were conserved at –20°C until analysis. Using 
this medium, the transport of glibenclamide in the absence 
(control) and presence (test) was measured.
In vivo experiment
Albino rats of either sex were randomly distributed into two 
groups of six animals in each group. Before experiment, all 
animals were fasted for 18 h and water ad libitum, water was 
withdrawn during experiment. After collection of initial 
blood samples, drugs were administered in the following 
order. Animals in Group A (GLB alone) received GLB 
at 3.6 mg/kg by oral route and rats in Group-B (GLB + 
CAR) received CAR (90 mg/kg) before 1 h of GLB (3.6 
mg/kg) treatment by oral route. The blood samples were 
collected from orbital sinuses using heparinized capillaries 
into a microcentrifugation tubes contain anticoagulant at 
1, 2, 4, 6, and 8 h after treatment. Plasma was separated by 
centrifugation and stored at −20°C until further analysis.
Bioanalytical method 
Glibenclamide concentrations from in vitro and in 
vivo samples were determined with a validated high-
performance liquid chromatography (HPLC) method. 
Briefly, the HPLC system consisted of a Waters 717 plus 
Autosampler (Waters Co., Milford, MA, USA), a Waters 
501 pump (Waters Co), and a 785 UV Detector (Applied 
Biosystems, Foster City, CA, USA) operated at 253 nm. The 
stationary phase was a Waters Symmetry C18 column (250 
mm × 4.6 mm, 5 μm, Waters Co.). The mobile phase used 
was 25 mM sodium phosphate/acetonitrile (65:35, v/v, pH 
= 3.5) at a flow rate of 1.0 mL/min. Glibenclamide and an 
internal standard (glipizide) were isolated from plasma by 
liquid–liquid extraction with methanol. The organic phase 
was separated and evaporated, and the remaining residue 
was reconstituted with 250 μL of mobile phase before 
applied to the HPLC system. The method was validated and 
found to be linear over the concentration range of 0.1–10 
μg/mL. Using a linear-weighted least squares regression, 
the lower limit of quantitation (LLQ) was 0.1 μg/mL. The 
intra-assay and inter-assay coefficients of variation (%CV) 
for the three quality control standards (0.25, 2.00, and 8.00 
μg/mL) were ≤10.2% and 4.9%, respectively. 
Pharmacokinetic analysis
The pharmacokinetic parameters of glibenclamide were 
calculated using a sophisticated tool known as Win Nonlin 
(4.1) and the parameters includes half-life (t1/2), clearance 
(Cl), volume of distribution (Vd), Cmax, Tmax, and area under 
the concentration-time curve (AUC).
Statistical analysis
Data were expressed as mean ± standard deviation (SD). 
The significance was determined by applying Student’s 
paired t-test.
RESULTS
In vitro experiments
The time course of glibenclamide transport across the 
everted ileum of healthy rats was shown in Figure 1. The 
percentage of glibenclamide remain present in ileum are P-gb-mediated intestinal secretion of glibenclamide
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shown in Figure 2, and results of carbamazepine inhibition 
at different time points are given in Table 1.
In vivo experiments
The plasma glibenclamide levels and pharmacokinetic 
parameters of glibenclamide such as AUC, T1/2, 
clearance, Vd, Cmax, and Tmax were altered significantly when 
comparing the results between GLB alone and combination 
group (GLB + CAR), and the results are shown in Tables 
2, 3, and Figure 3, respectively.
Figure 1: Transport of glibenclamide from serosal to mucosal side 
in the everted ileum of the healthy rat in presence and absence of 
carbamazepine (n = 6)
0 50 100 150
0
10
20
30
40
50
Glb
Glb+Car
Time(min)
C
u
m
u
l
a
t
i
v
e
 
a
m
o
u
n
t
 
o
f
 
g
l
i
b
e
n
c
l
a
m
i
d
e
(
µ
g
)
Figure  3:  Mean  ±  SD  plasma  concentration–time  profile  of 
glibenclamide (3.6 mg/mL) following pretreatment with carbamazepine 
(90 mg/kg) by oral administration in healthy rats (first day)
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Figure 2: Percentage of glibenclamide remaining in the everted ileum 
of healthy rat at different time points in the presence and absence of 
carbamazepine (n = 6)
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Table 2: Mean plasma glibenclamide concentration 
(µg/m) before and after oral administration of 
carbamazepine in healthy rats (n = 6)
Time (h) GLB GLB + CAR (First day)
0 0.00 ± 0.00 0.00 ± 0.00
1 0.78 ± 0.05 0.65 ± 0.04***
2 1.12 ± 0.32 1.38 ± 0.11
4 2.30 ± 1.03 2.34 ± 0.45
6 1.02 ± 0.23 1.67 ± 0.20***
8 0.72 ± 0.16 1.18 ± 0.25***
***Significant at P < 0.001 compared to glibenclamide control
Table 3: The comparison of pharmacokinetic 
parameters of glibenclamide (3.6 mg/mL) following 
pretreatment with carbamazepine (90 mg/kg) by oral 
administration in healthy rats (n = 6)
Parameter GLB GLB + CAR (First day)
AUC (µg/mL/h) 12.96 ± 4.88 20.95 ± 3.61***
K_HL (h–1) 2.24 ± 0.04 2.848 ± 0.24**
CL_F (mL/h) 42.31 ± 12.37 24.51 ± 4.51*
Tmax (h) 3.24 ± 0.06 4.10 ± 0.34***
Cmax (µg/mL) 1.46 ± 0.51 1.86 ± 0.24 
V_F (mL) 235.51 ± 45.82 147.73 ± 21.98**
*Significant at P < 0.05, **significant at P < 0.01, and ***significant at P < 0.001 
compared to glibenclamide control
Table 1: Glibenclamide (µg/mL) transport in the 
everted ileum of healthy rat in the presence and 
absence of carbamazepine
Time 
(min)
Glibenclamide-treated 
rats Mean ± SD
Glibenclamide and 
carbamazepine-treated 
rats Mean ± SD
P value
10 18.04 ± 1.6 1.44 ± 0.35 ***
20 21.22 ± 1.799 2.01 ± 0.269 ***
30 25.93 ± 0.4326 3.02 ± 0.627 ***
60 29.29 ± 2.133 3.52 ± 0.47 ***
90 40.21 ± 3.003 3.88 ± 0.345 ***
120 44.92 ± 1.27 4.28 ± 0.198 ***
*Significant at P < 0.05, **significant at P < 0.01, and ***significant at P < 0.001 
compared to glibenclamide controlSrirangam and Vidya Sagar. J Young Pharm. 2010;2(4): 379-383
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DISCUSSION
The pharmacological effects of a given drug compound 
are highly influenced by its pharmacokinetic behavior. 
Physicochemical properties are critical to the absorption, 
distribution, metabolism, and excretion of different 
xenobiotic compounds. However, it has now become 
apparent that different transport proteins play an important 
role in regulating the kinetic disposition of several drugs.[4]
In addition, clinically relevant drug interactions may 
occur after the concomitant administration of various 
compounds. The goal of the interaction studies between 
P-gp substrate and modulator has been addressed to 
identify the pharmacokinetic consequences and to predict 
the clinical outcome.
Several approaches are available to assess in vitro role 
of the specific proteins involved in the intestinal drug 
transport processes. However, the inference from the 
quantitative information obtained in the in vitro models to 
the in vivo situation may be limited. Thus, the prediction 
of the absorption process for a given P-gp substrate from 
in vitro assays could not be correlated to the in vivo results 
obtained when coadministration with a P-gp modulator 
is performed.[5] This outcome could be due to differences 
in the length of drug exposure, drug concentrations, 
concomitant induction of metabolic pathways, and extent 
of P-gp inhibition.[6]
Previous in vitro studies reported that GLB was actively 
secreted by multidrug-resistant tumor cells and by cells 
transfected with the gene coding for P-gp in the mouse. 
In addition, Barthe et al.[7] described the everted gut sac as 
a simple method to study intestinal absorption of digoxin 
in the presence or absence of verapamil or quinidine, 
obtaining a high correlation with the in vitro Caco-2 cells[8] 
and in vivo methods using knockout mice. The results of 
the current trial confirm that the everted sac technique is a 
useful in vitro model system for studying the P-gp-mediated 
efflux of GLB. The satisfactory results obtained with the 
use of the everted sac model to assess the P-gp-mediated 
modulation of GLB transport may be relevant to achieve 
reproducible results between the in vitro and in vivo assays.
The GLB concentration profiles measured in the ileal wall 
was markedly modified by the presence of CAR. The GLB 
tissue accumulation at 60 min of incubation in the presence 
of CAR was 20.1-fold higher compared with the incubation 
of GLB alone. Therefore, the rate of GLB accumulation in 
the intestinal wall was significantly higher in the presence 
of CAR. Thus, these results demonstrated that the everted 
sac technique was useful to compare the P-gp inhibition 
by modulators like CAR from different generations used 
at equimolar doses.
Interestingly, the results reported in our in vitro experiments 
were directly related to the observed in vivo changes in the 
pharmacokinetic behavior of GLB after coadministration 
with CAR [Table 3]. This is a relevant issue, considering that 
in previous studies, it was not always possible to reproduce 
in vivo results observed in in vitro. For instance, where as 
ketoconazole seemed to be the most valuable tool for 
increasing the intracellular quantity of [14C] moxidectin in 
rat hepatocyte cell cultures, the compound had no effect 
on the in vivo pharmacokinetics of moxidectin in lambs.[9-14]
CONCLUSION
The results from the studies reported here indicate that 
the plasma disposition of GLB was strongly affected by 
P-gp activity. In addition, we have demonstrated that GLB 
disposition kinetics in the intestinal tissues was significantly 
modified by the presence of CAR, under both in vivo and 
in vitro conditions, which confirms the relevance of this 
cellular transporter on the intestinal secretion of GLB. 
The characterization of the intestinal elimination pathway 
for GLB would be of therapeutic significance and the high 
GLB concentrations could be available at the target tissues, 
and which improving its clinical efficacy.
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